FindTrial
Sign In

Sodium Alginate antacid combination on quality of life, Tolerability and effectiveness in GERD patients

A Real World Evidenced Study to understand the effect Sodium Alginate antacid combination on quality of life, Tolerability and effectiveness in GERD patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070568
Enrollment
10000
Registered
2024-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K210- Gastro-esophageal reflux disease with esophagitis

Interventions

None listed

Sponsors

Alembic Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Ages: = 18 years 2. Genders Eligible for Study: both Males and Females 3. Patients who received oral Sodium alginate antacid suspension in the past for the management of GERD as per the local prescription data.

Exclusion criteria

Exclusion criteria: Patients those who had not received sodium alginate antacid suspension as per the local prescription data

Design outcomes

Primary

MeasureTime frame
Proportion of GERD patient achieving improvement in the quality of lifeTimepoint: Proportion of GERD patient having treatment related side effects on day 7—

Secondary

MeasureTime frame
Proportion of GERD patient having treatment related side effects on day 7Timepoint: From the Baseline to the 7 day after the treatment initiation;To evaluate the efficacy and safety profile of the patient who had received sodium alginate antacid Timepoint: To evaluate the efficacy and safety profile of the patient who had received sodium alginate antacid—

Countries

India

Contacts

Public ContactDr Dinesh Patil MBBS MD

Alembic Pharmaceuticals Limited

dinesh.patil@alembic.co.in9823953957

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026